Does Statin Benefits Patients with Heart Failure Undergoing Percutaneous Coronary Intervention? Findings from the Melbourne Interventional Group Registry

Ken Lee Chin, Rory Wolfe, Christopher M. Reid, Andrew Tonkin, Ingrid Hopper, Angela Brennan, Nick Andrianopoulos, Stephen J. Duffy, David Clark, Andrew Ajani, Danny Liew, for the Melbourne Interventional Group (MIG)

Research output: Contribution to journalArticleResearchpeer-review

1 Citation (Scopus)

Abstract

The effectiveness of statins in improving clinical outcomes among patients with heart failure (HF) undergoing percutaneous coronary intervention (PCI) is unclear. We examined the association between use of statins and clinical outcomes in patients with HF included in the Melbourne Interventional Group registry.

METHODS:
Patients were followed from 30 days to 1 year post-PCI for a primary composite outcome of all-cause mortality and hospitalisation for cardiovascular (CV) causes. Secondary outcomes included major adverse cardiac events (MACE, a composite of all-cause mortality, myocardial infarction and target vessel revascularisation) and hospitalisation for CV causes. Outcomes were compared between statin-treated and non-statin-treated patients (at 30 days post-PCI) using propensity scores to balance for risk factors.

RESULTS:
Among 991 patients included in the inverse probability-weighted Cox model, statin use had no significant effect on the primary composite outcome [adjusted hazard ratio (aHR), 1.03; 95% confidence interval (CI), 0.68 to 1.56; p = 0.89], nor MACE (aHR, 0.99; 95% CI, 0.54 to 1.84; p = 0.99) or hospitalisation for CV causes (HR, 1.13; 95% CI, 0.74 to 1.72; p = 0.57).

CONCLUSIONS:
Our results suggest that statin therapy may confer no significant benefits in patients with HF undergoing PCI. However, prospective randomised controlled trials are needed to provide more definitive answers.
Original languageEnglish
Pages (from-to)57-64
Number of pages8
JournalCardiovascular Drugs and Therapy
Volume32
Issue number1
DOIs
Publication statusPublished - 1 Feb 2018

Keywords

  • Heart failure
  • Percutaneous coronary intervention
  • Propensity score
  • Registry
  • Statins

Cite this

@article{7b1e00dcd28c4b9d96d6d7ded3f68c2e,
title = "Does Statin Benefits Patients with Heart Failure Undergoing Percutaneous Coronary Intervention? Findings from the Melbourne Interventional Group Registry",
abstract = "The effectiveness of statins in improving clinical outcomes among patients with heart failure (HF) undergoing percutaneous coronary intervention (PCI) is unclear. We examined the association between use of statins and clinical outcomes in patients with HF included in the Melbourne Interventional Group registry.METHODS:Patients were followed from 30 days to 1 year post-PCI for a primary composite outcome of all-cause mortality and hospitalisation for cardiovascular (CV) causes. Secondary outcomes included major adverse cardiac events (MACE, a composite of all-cause mortality, myocardial infarction and target vessel revascularisation) and hospitalisation for CV causes. Outcomes were compared between statin-treated and non-statin-treated patients (at 30 days post-PCI) using propensity scores to balance for risk factors.RESULTS:Among 991 patients included in the inverse probability-weighted Cox model, statin use had no significant effect on the primary composite outcome [adjusted hazard ratio (aHR), 1.03; 95{\%} confidence interval (CI), 0.68 to 1.56; p = 0.89], nor MACE (aHR, 0.99; 95{\%} CI, 0.54 to 1.84; p = 0.99) or hospitalisation for CV causes (HR, 1.13; 95{\%} CI, 0.74 to 1.72; p = 0.57).CONCLUSIONS:Our results suggest that statin therapy may confer no significant benefits in patients with HF undergoing PCI. However, prospective randomised controlled trials are needed to provide more definitive answers.",
keywords = "Heart failure, Percutaneous coronary intervention, Propensity score, Registry, Statins",
author = "Chin, {Ken Lee} and Rory Wolfe and Reid, {Christopher M.} and Andrew Tonkin and Ingrid Hopper and Angela Brennan and Nick Andrianopoulos and Duffy, {Stephen J.} and David Clark and Andrew Ajani and Danny Liew and {for the Melbourne Interventional Group (MIG)}",
year = "2018",
month = "2",
day = "1",
doi = "10.1007/s10557-018-6769-y",
language = "English",
volume = "32",
pages = "57--64",
journal = "Cardiovascular Drugs and Therapy",
issn = "0920-3206",
publisher = "Springer",
number = "1",

}

TY - JOUR

T1 - Does Statin Benefits Patients with Heart Failure Undergoing Percutaneous Coronary Intervention? Findings from the Melbourne Interventional Group Registry

AU - Chin, Ken Lee

AU - Wolfe, Rory

AU - Reid, Christopher M.

AU - Tonkin, Andrew

AU - Hopper, Ingrid

AU - Brennan, Angela

AU - Andrianopoulos, Nick

AU - Duffy, Stephen J.

AU - Clark, David

AU - Ajani, Andrew

AU - Liew, Danny

AU - for the Melbourne Interventional Group (MIG)

PY - 2018/2/1

Y1 - 2018/2/1

N2 - The effectiveness of statins in improving clinical outcomes among patients with heart failure (HF) undergoing percutaneous coronary intervention (PCI) is unclear. We examined the association between use of statins and clinical outcomes in patients with HF included in the Melbourne Interventional Group registry.METHODS:Patients were followed from 30 days to 1 year post-PCI for a primary composite outcome of all-cause mortality and hospitalisation for cardiovascular (CV) causes. Secondary outcomes included major adverse cardiac events (MACE, a composite of all-cause mortality, myocardial infarction and target vessel revascularisation) and hospitalisation for CV causes. Outcomes were compared between statin-treated and non-statin-treated patients (at 30 days post-PCI) using propensity scores to balance for risk factors.RESULTS:Among 991 patients included in the inverse probability-weighted Cox model, statin use had no significant effect on the primary composite outcome [adjusted hazard ratio (aHR), 1.03; 95% confidence interval (CI), 0.68 to 1.56; p = 0.89], nor MACE (aHR, 0.99; 95% CI, 0.54 to 1.84; p = 0.99) or hospitalisation for CV causes (HR, 1.13; 95% CI, 0.74 to 1.72; p = 0.57).CONCLUSIONS:Our results suggest that statin therapy may confer no significant benefits in patients with HF undergoing PCI. However, prospective randomised controlled trials are needed to provide more definitive answers.

AB - The effectiveness of statins in improving clinical outcomes among patients with heart failure (HF) undergoing percutaneous coronary intervention (PCI) is unclear. We examined the association between use of statins and clinical outcomes in patients with HF included in the Melbourne Interventional Group registry.METHODS:Patients were followed from 30 days to 1 year post-PCI for a primary composite outcome of all-cause mortality and hospitalisation for cardiovascular (CV) causes. Secondary outcomes included major adverse cardiac events (MACE, a composite of all-cause mortality, myocardial infarction and target vessel revascularisation) and hospitalisation for CV causes. Outcomes were compared between statin-treated and non-statin-treated patients (at 30 days post-PCI) using propensity scores to balance for risk factors.RESULTS:Among 991 patients included in the inverse probability-weighted Cox model, statin use had no significant effect on the primary composite outcome [adjusted hazard ratio (aHR), 1.03; 95% confidence interval (CI), 0.68 to 1.56; p = 0.89], nor MACE (aHR, 0.99; 95% CI, 0.54 to 1.84; p = 0.99) or hospitalisation for CV causes (HR, 1.13; 95% CI, 0.74 to 1.72; p = 0.57).CONCLUSIONS:Our results suggest that statin therapy may confer no significant benefits in patients with HF undergoing PCI. However, prospective randomised controlled trials are needed to provide more definitive answers.

KW - Heart failure

KW - Percutaneous coronary intervention

KW - Propensity score

KW - Registry

KW - Statins

UR - http://www.scopus.com/inward/record.url?scp=85040792351&partnerID=8YFLogxK

U2 - 10.1007/s10557-018-6769-y

DO - 10.1007/s10557-018-6769-y

M3 - Article

VL - 32

SP - 57

EP - 64

JO - Cardiovascular Drugs and Therapy

JF - Cardiovascular Drugs and Therapy

SN - 0920-3206

IS - 1

ER -